T-cell Lymphoma Clinical Trial
Official title:
A Sing-Arm, Open Clinical Pharmacology Study of Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in patients with Relapsed or Refractory T-cell Lymphoma. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.
This is an investigator initiated , single-arm, open-label clinical pharmacology study of RT-01 given via Intravenous injection in patients with advanced solid tumors. RT-01 will be administered on days 1 and 6, and every 8 weeks thereafter (up to 6 times). This study is planned to enroll 6 patients with Relapsed or Refractory T-cell Lymphoma. The purpose of this study is to assess the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00959686 -
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04712864 -
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01941680 -
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
|
||
Recruiting |
NCT05075460 -
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
|
Phase 3 | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT02017613 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT01854112 -
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
|
N/A | |
Completed |
NCT01553786 -
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
|
Phase 2 | |
Completed |
NCT00542919 -
A Study for Patients With Non-Hodgkin's Lymphomas
|
Phase 2 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Active, not recruiting |
NCT03952078 -
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
|
Phase 1 | |
Completed |
NCT02424045 -
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT01871675 -
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT00893516 -
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
|
Phase 2 | |
Completed |
NCT01902225 -
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
Recruiting |
NCT04264078 -
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
|
Early Phase 1 | |
Completed |
NCT00001582 -
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
|
||
Completed |
NCT00322985 -
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
|
Phase 2 |